MRNA Stock Price and Chart — BCBA:MRNA

Overview

Financials News Ideas Discussions Technicals Seasonals

Key facts today

Moderna's Phase 1/2 study of its avian flu vaccine, mRNA-1018, showed 97.8% of 300 participants developed protective antibodies. The U.S. will end funding for pre-pandemic flu vaccine development.

Analyze the impact Analyze the impact

About Moderna, Inc.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.